Dietary calcium intake above 750 mg does not provide added benefit against risk of fractures or osteoporosis, according to the results of a large prospective longitudinal cohort study reported in the May 24 issue of the British Medical Journal.
Dietary calcium intake above 750 mg does not provide added benefit against risk of fractures or osteoporosis, according to the results of a large prospective longitudinal cohort study reported in the May 24 issue of the British Medical Journal.
To investigate associations between long-term dietary calcium intake with risk of fracture of any type, hip fractures, and osteoporosis, investigators conducted a large, population-based prospective study, which consisted of 2 samples. The first was called the Swedish Mammography Cohort and included 61,433 women (born between 1914 and 1948) residing in 2 Swedish countries who responded to mailed invitations between 1987 and 1990 to a routine mammography screening. The primary outcomes were any fracture and hip fracture.
The second sample was a subcohort of 5,022 women from the Swedish Mammography Cohort, randomly selected between November 2003 and October 2009 and invited to undergo dual energy x-ray absorptiometry measurements, to provide blood and urine samples, and to have height and weight measurements taken. The secondary outcome was osteoporosis. A series of food-frequency questionnaires was used to gain in-depth knowledge of the participants’ diet, calcium intake, use of supplements and multivitamins, and lifestyle (postmenopausal oestrogen therapy and menopausal status, parity information, weight and height, smoking habits, and leisure time physical activity).
Results of the study showed an association between the lowest quintile of calcium intake and an increased risk of fractures and osteoporosis. Above the base quintile, there were only minor differences in risk. The rate of hip fracture increased in those with high dietary calcium intakes, however, the authors noted that this result should be cautiously interpreted.
“Our observational data suggest that in the prevention of osteoporotic fractures, emphasis should be placed on individuals with a low intake of calcium rather than increasing the intake of those already consuming satisfactory amounts,” the authors wrote.
Coalition promotes important acetaminophen dosing reminders
November 18th 2014It may come as a surprise that each year Americans catch approximately 1 billion colds, and the Centers for Disease Control and Prevention estimates that as many as 20% get the flu. This cold and flu season, 7 in 10 patients will reach for an over-the-counter (OTC) medicine to treat their coughs, stuffy noses, and sniffles. It’s an important time of the year to remind patients to double check their medicine labels so they don’t double up on medicines containing acetaminophen.
Support consumer access to specialty medications through value-based insurance design
June 30th 2014The driving force behind consumer cost-sharing provisions for specialty medications is the acquisition cost and not clinical value. This appears to be true for almost all public and private health plans, says a new report from researchers at the University of Michigan Center for Value-Based Insurance Design (V-BID Center) and the National Pharmaceutical Council (NPC).
Management of antipsychotic medication polypharmacy
June 13th 2013Within our healthcare-driven society, the increase in the identification and diagnosis of mental illnesses has led to a proportional increase in the prescribing of psychotropic medications. The prevalence of mental illnesses and subsequent treatment approaches may employ monotherapy as first-line treatment, but in many cases the use of combination of therapy can occur, leading to polypharmacy.1 Polypharmacy can be defined in several ways but it generally recognized as the use of multiple medications by one patient and the most common definition is the concurrent use of five more medications. The presence of polyharmacy has the potential to contribute to non-compliance, drug-drug interactions, medication errors, adverse events, or poor quality of life.
Medical innovation improves outcomes
June 12th 2013I have been diagnosed with stage 4 cancer of the pancreas, a disease that’s long been considered not just incurable, but almost impossible to treat-a recalcitrant disease that some practitioners feel has given oncology a bad name. I was told my life would be measured in weeks.